PMID- 19430005
OWN - NLM
STAT- MEDLINE
DCOM- 20090609
LR  - 20200203
IS  - 1569-8041 (Electronic)
IS  - 0923-7534 (Linking)
VI  - 20 Suppl 1
DP  - 2009 May
TI  - Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal 
      tumours: case reports.
PG  - i25-i30
LID - 10.1093/annonc/mdp076 [doi]
AB  - BACKGROUND: Sunitinib malate is approved multinationally for the treatment of 
      metastatic renal cell carcinoma (mRCC) and advanced imatinib-refractory 
      gastrointestinal stromal tumour (GIST). Greater exposure to sunitinib is 
      associated with improved efficacy. Therefore, minimising the impact of adverse 
      events (AEs) on patient quality of life is important to enable patients to 
      achieve optimal exposure to sunitinib and maximum clinical benefit. DESIGN: This 
      report describes four patient cases in which sunitinib was utilised for the 
      management of advanced malignancies: two cases describe mRCC patients who 
      received first-line sunitinib and two cases describe the use of targeted 
      therapies, including sunitinib, in patients with advanced GIST. RESULTS: In all 
      four cases, effective AE management enabled patients to receive long-term therapy 
      with sunitinib and achieve sustained clinical benefit. The two mRCC cases show 
      prolonged responses and manageable AEs with sunitinib. The two GIST cases 
      demonstrate that patients with imatinib-refractory GIST with KIT exon 9 
      mutations, including elderly patients, can achieve sustained responses to 
      sunitinib. CONCLUSIONS: These case studies support the long-term efficacy and 
      safety of sunitinib in the management of mRCC and imatinib-refractory GIST and 
      demonstrate how AE management can be used to optimise patient responses.
FAU - Schoffski, P
AU  - Schoffski P
AD  - Department of General Medical Oncology, University Hospitals Leuven, Leuven 
      Cancer Institute, Catholic University Leuven, Leuven, Belgium. 
      patrick.schoffski@uz.kuleuven.be
FAU - Bukowski, R
AU  - Bukowski R
FAU - Flodgren, P
AU  - Flodgren P
FAU - Ravaud, A
AU  - Ravaud A
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indoles)
RN  - 0 (Pyrroles)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - V99T50803M (Sunitinib)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy
MH  - Combined Modality Therapy
MH  - Female
MH  - Gastrointestinal Stromal Tumors/*drug therapy
MH  - Humans
MH  - Indoles/*therapeutic use
MH  - Intestinal Neoplasms/*drug therapy
MH  - Intestine, Small
MH  - Kidney Neoplasms/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Protein-Tyrosine Kinases/*antagonists & inhibitors
MH  - Pyrroles/*therapeutic use
MH  - Sunitinib
EDAT- 2009/05/14 09:00
MHDA- 2009/06/10 09:00
CRDT- 2009/05/12 09:00
PHST- 2009/05/12 09:00 [entrez]
PHST- 2009/05/14 09:00 [pubmed]
PHST- 2009/06/10 09:00 [medline]
AID - S0923-7534(19)57001-6 [pii]
AID - 10.1093/annonc/mdp076 [doi]
PST - ppublish
SO  - Ann Oncol. 2009 May;20 Suppl 1:i25-i30. doi: 10.1093/annonc/mdp076.